Bayer is sharing a new post-hoc analysis of self-reported sleep-related outcomes with LeKash® (elinzanetant) in women with moderate to severe vasomotor symptoms at the Menopause Society Annual Meeting. Company announcement - FT.com.
Bayer is sharing a new post-hoc analysis of self-reported sleep-related outcomes with LeKash® (elinzanetant) in women with moderate to severe vasomotor symptoms at the Menopause Society Annual Meeting. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in